
The active ingredient in popular type-2 diabetes drugs Wegovy and Ozempic may reduce the risk of Alzheimer's disease, according to a new study.
The study by researchers at Case Western Reserve School of Medicine in Cleveland found that type-2 diabetes patients taking semaglutide "compared to seven other anti-diabetic drugs."